Figure 6 | Scientific Reports

Figure 6

From: JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Figure 6

Pharmacokinetics and pharmacodynamics of orally administered JNJ-77242113 in a first-in-human study of healthy participants. (A) Mean plasma concentrations of JNJ-77242113 in healthy participants from Part 2 (Day 1 in multiple ascending dose cohorts). Error bars denote standard deviation. (B) Mean concentrations of IL-23–induced IFNγ in whole blood from participants after they had received a single oral dose of JNJ-77242113. Error bars denote standard error of the mean. IFN interferon, IL interleukin.

Back to article page